


ARCHIVES

OF

FAMILY MEDICINE

DECEMBER 1995



See Special Selection, page 997.

USE OF WARFARIN FOR NONVALVULAR
ATRIAL FIBRILLATION IN
NURSING HOME PATIENTS

INTERRUPTION IN THE
MEDICAL INTERACTION

HUMAN IMMUNODEFICIENCY VIRUS
SEROPREVALENCE IN COMMUNITY-BASED
PRIMARY CARE PRACTICES, 1990-1992

NONSURGICAL MANAGEMENT OF
OSTEOARTHRITIS, WITH AN EMPHASIS
ON NONPHARMACOLOGIC MEASURES



IN THIS ISSUE


CONCISE SUMMARIES
OF ADVANCES IN ALL
FIELDS AFFECTING
MEDICAL CARE
FOR WOMEN

FOLLOWS PAGE 1068

American Medical Association
Physicians dedicated to the health of America



ROBERT M. WHITE MEMORIAL LIBRARY
PAOLI MEMORIAL HOSPITAL
E THOMAS LANCASTER PIKE
PAOLI, PA 19301



1. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. *Lancet*. 1989;1:175-179.
2. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med*. 1990;323:1505-1511.
3. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. *Circulation*. 1991;84:527-539.
4. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. *J Am Coll Cardiol*. 1991;18:349-355.
5. Ezekowitz EM, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. *N Engl J Med*. 1992;327:1406-1412.
6. Laupacis A, Albers G, Dunn M, et al. Antithrombotic therapy in atrial fibrillation. *Chest*. 1992;102(suppl 4):426S-433S.
7. Starkey I, Warlow C. Controversies in neurology: the secondary prevention of stroke in patients with atrial fibrillation. *Arch Neurol*. 1986;43:66-68.
8. Sherman DG, Hart RG, Easton JD. The secondary prevention of stroke in patients with atrial fibrillation. *Arch Neurol*. 1986;43:68-70.
9. Hachinski V. Atrial fibrillation and recurrent stroke. *Arch Neurol*. 1986;43:70.
10. Cook DJ, Guyatt DG, et al. Rules of evidence and clinical recommendations on the use of antithrombotic agents. *Chest*. 1992;102(suppl 4):305S-311S.
11. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). *Am J Cardiol*. 1994;74:236-241.
12. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. *N Engl J Med*. 1995;333:5-10.
13. Finn SD. Aiming for safe anticoagulation. *N Engl J Med*. 1995;333:54-55.
14. Lackner TE, Battis GN. Use of warfarin for nonvalvular atrial fibrillation in nursing home patients. *Arch Fam Med*. 1995;4:1017-1026.
15. Tinetti ME. Factors associated with serious injury during falls by ambulatory nursing home residents. *J Am Geriatr Soc*. 1987;35:644-648.
16. Volicer L, Rheaume Y, Brown J, et al. Hospice approach to the treatment of patients with advance dementia of the Alzheimer type. *JAMA*. 1986;256:2210-2213.
17. Wetle T. Age as a risk factor for inadequate treatment. *JAMA*. 1987;258:516.
18. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. *Ann Intern Med*. 1992;116:901-904.
19. Avorn J. Benefit and cost analysis in geriatric care: turning age discrimination into health policy. *N Engl J Med*. 1984;310:1294-1301.
20. Beers MH, Ouslander JG, Fingold SF, et al. Inappropriate medication prescribing in skilled-nursing facilities. *Ann Intern Med*. 1992;117:684-689.

Only in JAMA . . .

Theme issues concentrate on critical issues in medicine today. Recently, JAMA: The Journal of the American Medical Association has explored these pertinent health topics, always from a clinical perspective and frequently in the full context of the social, economic, and political factors that affect them:

- Genetics and Molecular Medicine
- Perioperative Myocardial Ischemia
- Immunization
- Tobacco
- Medical Education
- HIV/AIDS
- Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiac Care
- Violence
- Mental Health
- Allergic and Immunologic Diseases

Plus, each year JAMA publishes its important CONTEMPO issue. This valuable issue highlights the latest developments in over 40 key medical specialties.

Don't miss a single issue. For important scientific medical information you cannot afford to miss, subscribe to JAMA today!

For information about subscribing, call 1-800-AMA-2350.

ARCHIVES

OF

FAMILY MEDICINE

Index to

Volume 4

January through December 1995

Editor

Marjorie A. Bowman, MD, MPA

Bowman Gray School of Medicine
Medical Center Boulevard
Winston-Salem, NC 27157-1084

Deputy Editor

Joseph C. Konen, MD, MSPH

Winston-Salem, NC

Assistant to Editor

Tina G. Sagartz

Associate Editors

Louise S. Acheson, MD, MS

Cleveland, Ohio

Charles E. Driscoll, MD

West Branch, Iowa

Steven C. Zweig, MD, MSPH

Columbia, Mo

Series Editor

Robert C. Rinaldi, PhD

Chicago, Ill

Editorial Board

Robert M. Bostick, MD, MPH, Winston-Salem, NC

W. Eugene Broadhead, MD, PhD, Danville, Va

Doug Campos-Outcalt, MD, MPA, Phoenix, Ariz

Nancy W. Dickey, MD, Chicago, Ill

Allen J. Dietrich, MD, Hanover, NH

John G. Halvorsen, MD, MS, Peoria, Ill

Arch G. Mainous III, PhD, Lexington, Ky

Patrick J. O'Connor, MD, MPH, St Paul, Minn

Christian N. Ramsey, Jr, MD, Lexington, Ky

Barbara D. Reed, MD, MSPH, Ann Arbor, Mich

Len Scarpinato, DO, FACP, FCCP, FAAFP,
Milwaukee, Wis

Thomas L. Speros, MD, Washington, NC

David H. Thom, MD, PhD, Palo Alto, Calif


IN HYPERTENSION OR ANGINA

CARDIZEM[®] CD

(diltiazem HCl) 120-, 180-, 240-, 300-mg Capsules

**FOR EFFECTIVE
24-HOUR CONTROL**

No other
diltiazem is
therapeutically
equivalent to
Cardizem CD¹



**A unique hemodynamic and safety profile
for hypertension or angina^{2,3}**

- A side-effect discontinuation rate comparable to placebo in both hypertension and angina trials³
- Most commonly reported side effects are headache (5.4%), bradycardia (3.3%), first-degree AV block (3.3%), dizziness (3.0%), edema (2.6%), ECG abnormality (1.6%), and asthenia (1.8%)²

Please see brief summary of prescribing information on adjacent page.